The emerging use of TNF-α inhibitors in orbital inflammatory disease

International Ophthalmology Clinics

Volumn 46, Issue 2, 2006, Pages 165-181

  Kapadia, Mitesh K ^a   Rubin, Peter A D ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOUBLE STRANDED DNA; ETANERCEPT; GAMMA INTERFERON; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERLEUKIN 12; INTERLEUKIN 6; METHOTREXATE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PREDNISONE; RADIOACTIVE IODINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID; THYROTROPIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ASPERGILLOSIS; AVASCULAR NECROSIS; BEHCET DISEASE; BONE MARROW SUPPRESSION; BRAIN PSEUDOTUMOR; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CHEMOSIS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CROHN DISEASE; DEMYELINATING DISEASE; DEMYELINATION; DIPLOPIA; DISEASE COURSE; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; ENDOCRINE OPHTHALMOPATHY; ENTERITIS; EXOPHTHALMOS; FEMALE INFERTILITY; FIBROBLAST; GASTROINTESTINAL SYMPTOM; GLAUCOMA; GRAVES DISEASE; HEMORRHAGIC CYSTITIS; HISTOPLASMOSIS; HUMAN; HYPERGLYCEMIA; INFECTION; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; LEUKOPENIA; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; LUPUS LIKE SYNDROME; LYMPHOMA; MOLLUSCUM CONTAGIOSUM; MOON FACE; MYOPATHY; NAUSEA; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; OPTIC NERVE DISEASE; ORBIT DISEASE; ORBIT INFLAMMATION; ORBIT PSEUDOTUMOR; OSTEOPOROSIS; PAIN; PERIORBITAL EDEMA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSYCHOSIS; RHEUMATOID ARTHRITIS; SCLERITIS; SEIZURE; SIDE EFFECT; SMOKING; STREPTOCOCCUS PNEUMONIAE; THYROID DISEASE; THYROTOXICOSIS; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; UVEITIS; VACCINATION; VIRUS REACTIVATION; WEIGHT GAIN;

EID: 33746166340     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200604620-00014     Document Type: Conference Paper

References (68)

1. Teng CS, Yeo PP. Ophthalmic Graves's disease: natural history and detailed thyroid function studies. Br Med J. 1977;1:273-275.
2. Vestergaard P. Smoking and thyroid disorders - a meta-analysis. Eur J Endocrinol. 2002;146:153-161.
3. Bartley GB, Fatourechi V, Kadrmas EF, et al. The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol. 1995;120:511-517.
4. Wakelkamp IM, Bakker O, Baldeschi L, et al. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol (Oxford). 2003;58:280-287.
5. Metcalf R, Weetman A. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol. 1994;40:67-72.
6. Smith TJ. Novel aspects of orbital fibroblast pathology. J Endocrinol Invest. 2004;27:246-253.
7. Mizokami T, Salvi M, Wall JR. Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon?. J Endocrinol Invest. 2004;27:221-229.
8. Heufelder A, Bahn R. Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves' ophthalmopathy. Eur J Clin Invest. 1993;23:10-17.
9. Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121:284-290.
10. Bartley GB, Fatourechi V, Kadrmas EF, et al. The treatment of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121:200-206.
11. Boulos PR, Hardy I. Thyroid-associated orbitopathy: a clinicopathologic and therapeutic review. Curr Opin Ophthalmol. 2004;15:389-400.
12. Mombaerts I, Goldschmeding R, Schlingemann RO, et al. What is orbital pseudotumor?. Surv Ophthalmol. 1996;41:66-78.
13. Berger JW, Rubin PA, Jakobiec FA. Pediatric orbital pseudotumor: case report and review of the literature. Int Ophthalmol Clin. 1996;36:161-177.
14. Mottow LS, Jakobiec FA. Idiopathic inflammatory orbital pseudotumor in childhood. I. Clinical characteristics. Arch Ophthalmol. 1978;96:1410-1417.
15. Mombaerts I, Koornneef L. Current status in the treatment of orbital myositis. Ophthalmology. 1997;104:402-408.
16. Yuen SJ, Rubin PA. Idiopathic orbital inflammation: ocular mechanisms and clinicopathology. Ophthalmol Clin North Am. 2002;15:121-126.
17. Yuen SJ, Rubin PA, Yuen SJ, et al. Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. Arch Ophthalmol. 2003;121:491-499.
18. Lanciano R, Fowble B, Sergott RC, et al. The results of radiotherapy for orbital pseudotumor. Int J Radiat Oncol Biol Phys. 1990;18:407-411.
19. Sergott RC, Glaser JS, Charyulu K. Radiotherapy for idiopathic inflammatory orbital pseudotumor. Indications and results. Arch Ophthalmol. 1981;99:853-856.
20. Donaldson SS, McDougall IR, Egbert PR, et al. Treatment of orbital pseudotumor (idiopathic orbital inflammation) by radiation therapy. Int J Radiat Oncol Biol Phys. 1980;6:79-86.
21. Orcutt JC, Garner A, Henk JM, et al. Treatment of idiopathic inflammatory orbital pseudotumours by radiotherapy. Br J Ophthalmol. 1983;67:570-574.
22. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168-199.
23. Ebner R, Devoto MH, Weil D, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol. 2004;88:1380-1386.
24. Marcocci C, Bartalena L, Panicucci M, et al. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study. Clin Endocrinol (Oxford). 1987;27:33-42.
25. Dietlein M, Dederichs B, Weigand A, et al. Radioiodine therapy and thyroid-associated orbitopathy: risk factors and preventive effects of glucocorticoicls. Exp Clin Endocrinol Diabetes. 1999;107:S190-S194.
26. Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab. 2001;86:3562-3567.
27. Mombaerts I, Schlingemann RO, Goldschmeding R, et al. Are systemic corticosteroids useful in the management of orbital pseudotumors? Ophthalmology. 1996;103:521-528.
28. Goldberg RA, McCann JD, Shorr N. Idiopathic orbital inflammatory disease. Arch Ophthalmol. 2004;122:1092. Author reply -3.
29. Chiu CS, Rubin PA. Pharmacotherapies and nonpharmacotherapies for orbital inflammatory diseases. Int Ophthalmol Clin. 2004;44:165-185.
30. Gayno JP, Strauch G. Ciclosporine and Graves' ophthalmopathy. Horm Res. 1987;26:190-197.
31. Wemeau JL, Caron PH, Beckers A, et al. Octreotide-LAR treatment in patients with Graves' orbitopathy: clinical results of a four-month randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab. 2004. (epub ahead of print).
32. Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2004;89:5910-5915.
33. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med. 2004; 350:2167-2179.
34. Gisondi P, Gubinelli E, Cocuroccia B, et al. Targeting tumor necrosis factor-alpha in the therapy of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:175-183.
35. Korzenik JR. Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab. Gastroenterol Clin North Am. 2004;33:285-301.
36. Hanauer SB. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev Gastroenterol Disord. 2004;4:S18-S24.
37. Adalimumab (Humira) package insert. 7-30-2004.
38. Etanercept (Enbrel) package insert. 9-27-2004.
39. Infliximab (Remicade) package insert. 12-17-2004.
40. FDA Center for Drug Evaluation and Research database. Available at URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction= Search. Search_Drug_Name. Accessed on 2-25-2005.
41. Zink A, Listing JD, Kary S, et al. Treatment continuation in patients receiving biologicals or conventional DMARD therapy. Ann Rheum Dis. 2005. (epub ahead of print).
42. Hiromatsu Y, Yang D, Bednarczuk T, et al. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metab. 2000;85:1194-1199.
43. Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother. 2000;34:161-164.
44. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine. 1995;7:251-259.
45. Infliximab (Remicade) package insert. 9-27-2004.
46. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:1451-1459.
47. den Broeder A, van de Putte L, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol. 2002;29:2288-2298.
48. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130:478-486.
49. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Safety. 2004;27:307-324.
50. FDA Briefing Document. Update on TNF-alpha blocking agents. Available at URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm. Accessed on 2/25/2005.
51. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
52. Fleischmann RM, Baumgartner SW, Tindall EA, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. J Rheumatol. 2003;30:691-696.
53. Cursiefen C, Grunke M, Dechant C, et al. Multiple bilateral eyelid molluscum contagiosum lesions associated with TNFalpha-antibody and methotrexate therapy. Am J Ophthalmol. 2002;134:270-271.
54. Francis GS. TNF-alpha and heart failure. The difference between proof of principle and hypothesis testing. Circulation. 1999;99:3213-3214.
55. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107: 3133-3140.
56. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343: 1594-1602.
57. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45.
58. Mohan AK, Edwards ET, Cote TR, et al. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet. 2002;360:646.
59. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862-2869.
60. Drugstore.com Prescription Price Checker. Available at URL: http://www.drugstore. com. Accessed 2-25-2005.
61. Anonymous. Adalimumab (humira) for rheumatoid arthritis. Med Lett Drugs Ther. 2003;45:25-27.
62. Reiff A, Takei S, Sadeghi S, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001;44:1411-1415.
63. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121:437-440.
64. Mangge H, Heinzl B, Grubbauer HM, et al. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int. 2003;23:258-261.
65. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology. 2002;109:2342-2346.
66. El-Shabrawi Y, Hermann J. Anti-TNF alpha therapy in chronic necrotizing scleritis resistant to standard immunomodulatory therapy in a patient with Wegener's granulomatosis. Eye. 2004. (epub ahead of print).
67. Paridaens D, van denBosch WA, van der Loos TL, et al. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye. 2004. (epub ahead of print).
68. Garrity JA, Coleman AW, Matteson EL, et al. Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol. 2004;138:925-930.